105 related articles for article (PubMed ID: 8112644)
1. Limited-field radiotherapy as salvage treatment of localized persistent or recurrent epithelial ovarian cancer.
Davidson SA; Rubin SC; Mychalczak B; Saigo PE; Lewis JL; Chapman D; Hoskins WJ
Gynecol Oncol; 1993 Dec; 51(3):349-54. PubMed ID: 8112644
[TBL] [Abstract][Full Text] [Related]
2. Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
Chang JS; Kim SW; Kim YJ; Kim JY; Park SY; Kim JH; Jang TK; Kim YB
Gynecol Oncol; 2018 Oct; 151(1):39-45. PubMed ID: 30146110
[TBL] [Abstract][Full Text] [Related]
3. Involved-field radiation therapy for locoregionally recurrent ovarian cancer.
Brown AP; Jhingran A; Klopp AH; Schmeler KM; Ramirez PT; Eifel PJ
Gynecol Oncol; 2013 Aug; 130(2):300-5. PubMed ID: 23648467
[TBL] [Abstract][Full Text] [Related]
4. Results of post-operative abdomino-pelvic radiotherapy in intermediate- and high-risk epithelial ovarian carcinoma.
Mosalaei A; Kazerooni T
Eur J Cancer Care (Engl); 2008 Jul; 17(4):371-6. PubMed ID: 18537815
[TBL] [Abstract][Full Text] [Related]
5. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
Firat S; Murray K; Erickson B
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):201-7. PubMed ID: 12909234
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1998 Nov; 71(2):190-5. PubMed ID: 9826459
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
9. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
Wong CN; Wong CN; Liu FS
Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
[TBL] [Abstract][Full Text] [Related]
10. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
12. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
[TBL] [Abstract][Full Text] [Related]
13. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
15. Salvage whole abdomen radiation therapy: its role in ovarian cancer.
Reddy S; Lee MS; Yordan E; Graham J; Sarin P; Hendrickson FR
Int J Radiat Oncol Biol Phys; 1993 Nov; 27(4):879-84. PubMed ID: 8244818
[TBL] [Abstract][Full Text] [Related]
16. Selective irradiation for the treatment of recurrent ovarian carcinoma involving the vagina or rectum.
Firat S; Erickson B
Gynecol Oncol; 2001 Feb; 80(2):213-20. PubMed ID: 11161862
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
18. Impact of tumor volume-directed involved field radiation therapy integrated in the management of recurrent ovarian cancer.
Albuquerque KV; Singla R; Potkul RK; Smith DM; Creech S; Lo S; Emami B
Gynecol Oncol; 2005 Mar; 96(3):701-4. PubMed ID: 15721414
[TBL] [Abstract][Full Text] [Related]
19. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure.
Corn BW; Lanciano RM; Boente M; Hunter WM; Ladazack J; Ozols RF
Cancer; 1994 Dec; 74(11):2979-83. PubMed ID: 7525039
[TBL] [Abstract][Full Text] [Related]
20. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy.
Nelson G; Randall M; Sutton G; Moore D; Hurteau J; Look K
Gynecol Oncol; 1999 Nov; 75(2):211-4. PubMed ID: 10525373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
